130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
Rank Status Study
1 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
2 Completed Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults
Condition: HIV Infections
Interventions: Biological: PennVax B;   Biological: IL-12;   Biological: IL-15
3 Recruiting Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials
Conditions: HIV Infection;   HIV Seronegativity
Intervention:
4 Completed Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection
Condition: HIV Infections
Intervention: Biological: MVA-mBN32
5 Completed Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults
Condition: HIV Infections
Interventions: Biological: MRKAd5 HIV-1 gag/pol/nef;   Other: Placebo
6 Completed A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
Condition: HIV Infections
Interventions: Biological: Aluminum hydroxide;   Biological: QS-21;   Biological: rgp120/HIV-1MN
7 Completed Safety of and Immune Response to a DNA HIV Vaccine Followed By an Adenoviral Vector HIV Vaccine in Healthy Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA016-00-VP;   Biological: VRC-HIVADV014-00-VP;   Biological: VRC-HIVDNA016-00-VP placebo;   Biological: VRC-HIVADV014-00-VP placebo
8 Completed Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: VRC-HIVADV014-00-VP
9 Completed A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: gp160 Vaccine (Immuno-AG)
10 Unknown  Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: HIV-1 DNA vaccine with protein vaccine boost
11 Completed Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: pGA2/JS2 Plasmid DNA Vaccine
12 Completed A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203);   Biological: Aluminum hydroxide;   Biological: MF59;   Biological: rgp120/HIV-1MN
13 Completed A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (Immuno-AG)
14 Completed Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA016-00-VP;   Biological: VRC-HIVADV014-00-VP;   Biological: VRC-DILUENT013-DIL-VP;   Biological: VRC-HIVADV014-00-VP  placebo
15 Completed Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: MRKAd5 HIV-1 gag/pol/nef
16 Completed A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)
Condition: HIV Infections
Intervention: Biological: HIV-1 C4-V3 Polyvalent Peptide Vaccine
17 Completed Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC(2)120(B,MN)GNP (vCP1452)
18 Completed A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1;   Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1;   Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: rgp120/HIV-1 SF-2
19 Completed A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1;   Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65)
20 Completed Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults
Condition: HIV Infections
Interventions: Biological: pGA2/JS7 DNA;   Biological: Modified vaccinia Ankara/HIV62

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years